Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Deferred tax assets — Stock-based compensation by Year
Deferred tax assets — Stock-based compensation ($M) ($M)
Vertex Pharmaceuticals Deferred tax assets — Stock-based compensation: $172M in FY2025, up 4.6% from a year earlier. That is the highest of the 11 years on record here.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-K Note (Income Taxes).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Deferred tax assets — Stock-based compensation ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 172 | +4.6% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 164 | +13.9% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 144 | +15.8% | Form 10-K (filed 2025-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 124 | +31.5% | Form 10-K (filed 2024-02-15) ↗ |
| FY2021 | Dec 31, 2021 | 94.6 | +6.1% | Form 10-K (filed 2023-02-10) ↗ |
| FY2020 | Dec 31, 2020 | 89.2 | +4.7% | Form 10-K (filed 2022-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 85.2 | -9.3% | Form 10-K (filed 2021-02-11) ↗ |
| FY2018 | Dec 31, 2018 | 93.9 | +12.9% | Form 10-K (filed 2020-02-13) ↗ |
| FY2017 | Dec 31, 2017 | 83.2 | -24.7% | Form 10-K (filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 111 | +18.3% | Form 10-K (filed 2018-02-15) ↗ |
| FY2015 | Dec 31, 2015 | 93.4 | – | Form 10-K (filed 2017-02-23) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Deferred tax assets — Stock-based compensation ($M), annual FY2015–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/dta-sbc
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.